Curative Therapies for Hepatitis C Virus Infection in Patients with Kidney Disease

Ian A. Strohbehn, Rituvanthikaa Seethapathy, Meghan Lee, and Meghan E. Sise

Abstract

Through the discovery of direct-acting antiviral therapies over the last decade, hepatitis C virus (HCV) has been transformed from a highly morbid and potentially fatal chronic viral infection to a curable illness. HCV is common in patients with kidney disease, is a risk factor for progression of CKD, and is associated with higher morbidity and mortality in patients receiving dialysis, and leads to worse allograft and patient outcomes in recipients of kidney transplants. Clinical trial and real-world data of direct-acting antivirals in patients with kidney disease demonstrate extremely high cure rates and favorable adverse event profiles. This review covers the transformative effects of curative HCV therapies on patients with kidney disease, including patients with CKD, ESKD, and those who have received a kidney transplant.

Introduction

Untreated hepatitis C virus (HCV) infection is a major cause of chronic and end stage liver disease in both the developed and developing world. Beyond causing liver disease, HCV can affect multiple organ systems and is both a cause and complication of CKD. In fact, up to 10% of the patients infected with HCV in the United States have CKD (1). HCV infection also has important implications for patients with ESKD and recipients of kidney transplants (Figure 1). Direct-acting antiviral (DAA) therapies for HCV, which have been discovered and widely deployed over the last decade, have rapidly changed HCV from a chronic, potentially deadly disease to a readily curable illness. A recent, large, prospective cohort study of nearly 10,000 patients showed that DAAs decreased all-cause mortality and hepatocellular carcinoma risk (2). This review covers the far-reaching effect of curative HCV therapies on patients with kidney disease.

Evolution of Modern DAA Treatments for HCV

Historically, HCV drug therapy depended on the combination of IFN-α, in standard form or pegylated form, and ribavirin. IFN and ribavirin-based therapies required 6–12 months of treatment with suboptimal efficacy (<50%) and commonly resulted in severe side effects, including neuropsychiatric changes, hematologic abnormalities, flu-like symptoms, and autoimmune toxicities (3–6). In 2011, the first-generation DAAs, boceprevir and telaprevir, were approved in combination with ribavirin; however, despite increased effectiveness, these medications were poorly tolerated (7–10). Boceprevir and telaprevir were quickly supplanted by sofosbuvir, a nonstructural protein 5B (NS5B) polymerase approved in 2013, which was paired with ribavirin and led to outstanding cure rates and significantly fewer side effects (11,12). Quickly, the field moved to combination DAA therapies; by pairing agents that target multiple components of HCV’s replicative machinery, including HCV’s NS3/4A protease, NS5A protein, and NS5B polymerase, combination DAA therapy can overcome resistance (Figure 2). Combination DAA therapy allows for IFN- and ribavirin-free regimens and are extremely well tolerated. Because DAAs do not rely on the host immune response, they have demonstrated outstanding cure rates across essentially all previously difficult-to-treat populations, including patients who are immunosuppressed due to organ transplantation or HIV coinfection.

DAAs are largely considered non-nephrotoxic, with large series showing extremely low rates of AKI attributed to DAA therapy (13). However, small case series have linked DAA use with lupus-like GN and podocytopathies, and there have also been case reports of acute interstitial nephritis (14–17). However, these rare reports should not deter the use of DAAs in patients with CKD.

DAAs in Patients with an eGFR of <30 ml/min per 1.73 m²

Sofosbuvir, the first modern DAA, is a uridine nucleotide analogue prodrug whose active metabolite inhibits HCV’s NS5B polymerase and is active against all genotypes of HCV (18). Because sofosbuvir and its active metabolite are renally eliminated, patients with an eGFR of <30 ml/min per 1.73 m² were excluded from the initial registrational trials of all sofosbuvir-based DAA combinations. The first DAA combination studied in patients with advanced CKD and ESKD was grazoprevir (NS3/4A protease inhibitor) combined
with elbasvir (an NS5A inhibitor). Both of these agents are hepatically metabolized, and their exposure in patients with kidney failure is not substantially increased. The C-SURFER (Hepatitis C: Study to Understand Renal Failure’s Effect on Responses) study, published in 2015, was a phase 3 trial that enrolled 235 patients with genotype 1 HCV infection and CKD stage 4 or 5 or those on dialysis (19). Sustained virologic response at 12 weeks (virologic cure) was 94%. The most common adverse events were headache, nausea, and fatigue, occurring at similar frequencies in patients receiving active and placebo drugs. Two trials in the advanced CKD and dialysis population using glecaprevir and pibrentasvir (a hepatically metabolized NS3/4A protease and NS5A inhibitor combination that treats all genotypes of HCV infection) have also shown outstanding cure rates and excellent safety profiles in patients with kidney failure, with no treatment-related severe adverse events in either trial (20, 21).

Despite early concerns about accumulation of sofosbuvir and its active metabolite (22), multiple “real-world” studies showed that sofosbuvir-based DAAs were effective and
Table 1. Clinical trials involving DAAs in patients with an eGFR of <30 ml/min per 1.73 m² or those on dialysis and in recipients of kidney transplants

| Trial | Regimen | Number Enrolled, Study Design | Patient Population | HCV Cure Rate (%) | Overall SAE Rate |
|-------|---------|-------------------------------|-------------------|-------------------|-----------------|
| C-SURFER; Roth et al. (19) | Elbasvir/grazoprevir | 235, randomized controlled trial | CKD 4/5, ESKD | 94 | 14% in immediate treatment group; 17% in deferred treatment group (no SAE considered treatment related in immediate treatment group; treatment-related SAE in deferred treatment group was increased lipase) |
| Expedition-4; Gane et al. (20) | Glecaprevir/pibrentasvir | 104, single arm | CKD 4/5, ESKD | 98 | 24% SAE, none treatment related |
| Expedition-5; Lawitz et al. (21) | Glecaprevir/pibrentasvir | 101, single arm | CKD 3b/4/5, ESKD | 97 | 12% SAEs, none treatment related |
| Borgia et al. (26) | Sofosbuvir/velpatasvir | 59, single arm | ESKD | 95 | 19% SAEs, none treatment related |
| Chuang et al. (46) | Sofosbuvir/ledipasvir | 95, single arm | ESKD | 94 | 13% SAEs, none treatment related |
| Colombo et al. (56) | Sofosbuvir/ledipasvir | 114, randomized, open-label study | Transplant recipients, eGFR ≥40 ml/min per 1.73 m² | 100 | 11% SAEs (three treatment-related SAEs: syncope, pulmonary embolism, and serum creatinine increase) |
| Reau et al. (57)* | Glecaprevir/pibrentasvir | 20 kidney transplants, single arm, open label | Transplant recipients, no eGFR cutoff | 100 | 8% in overall cohort (n=20 kidney transplants, n=80 liver transplant; two treatment-related SAEs—sinusitis and abnormal hepatic function) |

DAA, direct-acting antiviral; HCV, hepatitis C virus; SAE, serious adverse event; C-SURFER, Hepatitis C: Study to Understand Renal Failure’s Effect on Responses; Expedition-4, A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection; Expedition-5, A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Renally-Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection.

*In this study, overall cohort was n = 100, out of which 80 patients had liver transplant and 20 patients had a kidney transplant. The HCV cure rate was 20 out of 20 for patients with a kidney transplant, and the SAEs were 8% for the overall cohort.
well tolerated in the dialysis populations (23,24), and other analyses showed extremely low rates of kidney injury in patients receiving sofosbuvir-based DAAs (13,25). In 2019, the results of two clinical trials of sofosbuvir-containing therapies, conducted in patients with ESKD on dialysis, demonstrated outstanding safety and efficacy and ultimately led to expansion of the Food and Drug Administration label for sofosbuvir-based DAAs to include patients with all levels of kidney function, including those with dialysis dependence (Table 1). The first was a phase 2, open-label study of 95 patients on dialysis who were treated with sofosbuvir and ledipasvir for 12 weeks, in which 89 patients (94%) were cured. Another was a study of sofosbuvir/velpatasvir in 59 patients on dialysis, in which 56 patients (95%) were cured (26). In both trials, there were no treatment-related serious adverse events.

Current treatment guidelines, endorsed by the American Association of Liver Disease (AASLD) and Infectious Diseases Society of America, are available at HCVguideline.org. Guidelines recommend the use of a pan-genotypic regimen when possible, with no dose adjustments needed for kidney disease.

HCV and CKD
HCV infection is a major cause of mixed (type II) cryoglobulinemia syndrome, a systemic vasculitis characterized by involvement of small to medium-sized vessels that causes palpable purpura, neuropathy, arthralgia, and GN. The pathogenesis of HCV-triggered mixed cryoglobulinemia syndrome is hypothesized to be due to chronic stimulation of B lymphocytes, with excess production of autoantibodies and cryoglobulins. Cryoglobulinemic GN may result due to the affinity of IgM rheumatoid factor for cellular fibronectin in the mesangial matrix. Immune complex deposition leads to complement activation, inflammatory cytokine release, vasculitis, fibrinoid necrosis, and crescent formation. Kidney biopsy specimens demonstrate a membranoproliferative pattern of injury with mesangial hypercellularity and expansion, endocapillary proliferation, monocytic infiltration, thickened capillary loops, large eosinophilic, and intraluminal deposits showing positive staining for Periodic acid–Schiff, which are referred to as “pseudothrombi” because they may fill the entire capillary lumen. Vasculitis of small and medium-sized renal arteries is present in some cases. Immunofluorescence typically shows C3, IgM, and IgG granular deposits in the capillary wall and mesangium. The subendothelial deposits seen on electron microscopy may have tubular and crystalline patterns typical of cryoglobulinemia. Clinical manifestations of GN range from asymptomatic microscopic hematuria to AKI from rapidly progressive GN, or even nephrotic syndrome. Laboratory evaluation demonstrates marked hypocomplementemia, with a greater reduction in C4 than C3, and the majority of patients have an elevated rheumatoid factor. Despite the fact that cryoglobulinemic GN is only found in approximately 1%–2% of patients with HCV, biopsy and autopsy series in patients with advanced liver disease have shown that subclinical glomerular abnormalities are actually much more common, found in >50% of patients with HCV (27,28).

Because IFN- and ribavirin-based therapies for HCV were rarely efficacious in curing HCV in patients with cryoglobulinemic GN, it was customary that rituximab and corticosteroids were used to treat HCV-related cryoglobulinemic GN. However, given that multiple studies have shown the DAAs are efficacious in patients with cryoglobulinemic GN (29,30), the Kidney Disease Improving Global Outcomes guidelines now recommend that DAAs be used as first-line treatment for cryoglobulinemic GN and that immunosuppression with rituximab-based therapy should be reserved for patients with severe manifestations of vasculitis (rapidly progressive GN, pulmonary hemorrhage) or those with persistent GN after completing DAAs (31). It is important to note that de novo cryoglobulinemic GN can occur after cure of HCV with DAAs, although the incidence is rare (32). In this instance, rituximab-based immunosuppression treatment should be used.

Various other histologic types of kidney diseases are reported in association with HCV infection, including membranous nephropathy, FSGS, fibrillary GN, immunotactoid GN, IgA nephropathy, thrombotic microangiopathy, renal vasculitis, and interstitial nephritis (33–35). The effect of DAAs on these lesions is less well studied.

Beyond causing glomerular disease, HCV is associated with an increased risk of progression to ESKD in patients with CKD. Population studies in multiple settings have highlighted this important association, particularly in patients with HIV coinfection (33,36–38). This is likely due to systemic effects of HCV, which include promoting immune activation, worsening insulin resistance, and accelerating atherosclerosis, each of which could affect the development and progression of CKD. Recent data suggest that DAAs therapy may slow eGFR decline in patients with CKD and decrease the risk of ESKD (13,25). Two recent studies have highlighted the importance of curing HCV to stabilize or improve eGFR in patients with HCV (39,40).

HCV and Dialysis
HCV infection is more commonly seen in patients on dialysis than in the general patient, it is estimated to be three-fold higher than the general population (41). Patients on dialysis may be more likely to acquire HCV from blood transfusions, prior transplantation, prior or current intravenous drug use, and nosocomial infection. Dialysis vintage is associated with risk of HCV infection in patients on dialysis (41). Unfortunately, even in the current era, breakdown in infection control practices and universal precautions have led to HCV outbreaks in dialysis centers (42,43). Patients on dialysis infected with HCV have high mortality rates, and are six times more likely to die of liver disease; they are also more likely to be hospitalized and have lower quality-of-life scores (44) Historically, only 1% of patients on dialysis received treatment for HCV infection due to the low response rate and poor tolerability of IFN- and ribavirin-based therapies (45). However, DAAs have now prospectively been studied in patients on dialysis (Table 1) and are safe and efficacious (19–21,26,46). Nephrologists who manage patients on dialysis must identify HCV infection and advocate for their patients to undergo treatment, because the current AASLD guidelines suggest that anyone with >1 year life expectancy
### Table 2. Clinical trials involving DAAs in transplant recipients without HCV who have received kidneys from donors with HCV

| Trial                    | Regimen                      | Number Enrolled, Study Design | Timing of DAA | HCV Cure Rate (%) | Study Notes                                                                                                                                          |
|--------------------------|------------------------------|-------------------------------|---------------|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| THINKER-1; Goldberg et al. (72) | Elbasvir/grazoprevir        | 10, single arm                | POD3          | 100               | 1 case of FSGS (proteinuria adjudicated as being possibly related to HCV and with substantial improvement after treatment)                           |
| THINKER-2; Reese et al. (71)   | Elbasvir/grazoprevir        | 10, single arm                | POD3          | 100               | 5 DGF (THINKER-1 group); 1 treatment failure with successful retreatment with DAAs                                                                 |
| EXPANDER; Durand et al. (61) | Elbasvir/grazoprevir (sofosbuvir if not genotype 1 or 4)
  a | 10, single arm               | Preoperative                 | 100           | No AEs related to treatment                                                                                                                           |
| Sise et al. (69)          | Elbasvir/grazoprevir        | 8, single arm                 | Preoperative  | 100               | 1 immediate graft failure, 3 DGF                                                                                                                       |
| Durand et al. (67)        | Glecaprevir/pibrentasvir
  b | 10, single arm                | Preoperative                 | 100           | 1 graft failure                                                                                                                                 |
| Sise et al. (68)          | Glecaprevir/pibrentasvir    | 30, single arm                | POD3          | 100               | 3 acute rejection within first 6 months, 7 DGF                                                                                                       |
| Terrault et al. (64)      | Sofosbuvir/velpatasvir      | 11, single arm                | Started once viremia detected, median POD17    | 100               | 2 with delayed graft function, 3 with transaminase elevations 4–7× ULN; 10 were treated with DAA (1 never developed viremia); included liver and kidney transplants |
| Feld et al. (65)          | Glecaprevir/pibrentasvir
  plus ezetimibe | 10, single arm                | Preoperative                 | 100           | 1 grade 3 elevated ALT (peak 650 U/L), possibly related to treatment; included lung, heart, kidney, and pancreas transplants |

**DAAs, direct-acting antivirals; HCV, hepatitis C virus; POD, postoperative day; DGF, delayed graft function; AE, adverse event; ULN, upper limit of normal; ALT, alanine am inotransferase; THINKER, Transplanting Hepatitis C kidneys Into Negative Kidney Recipients; EXPANDER, Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients.**

*a In patients with genotype 1a with nonstructural protein 5A resistance-associated substitutions, ribavirin was added to grazoprevir/elbasvir and therapy duration was extended to 16 weeks, as per standard of care.

*b In this study, patients received only 4 weeks of glecaprevir/pibrentasvir.
should be treated DAAs (47). Future research will be needed to determine if DAAs mitigate the known adverse association of HCV on quantity and quality of life for patients on dialysis. In 2016, the World Health Organization established the goal of eliminating HCV by 2030 (48). Strategies to eradicate HCV from dialysis units should consider DAA treatment as prevention. Indeed, reports of targeted outreach efforts to screen and treat HCV in dialysis have resulted in elimination of HCV entirely from dialysis units, demonstrating these efforts can be successful (49). However, it is important to note that, in some regions, being infected with HCV can shorten transplant waitlist times, so HCV treatment decisions in patients on the transplant waitlist should involve a discussion with local transplant center physicians.

HCV in Recipients of Kidney Transplants

Untreated HCV has been linked to lower graft and patient survival after kidney transplantation. HCV-associated liver disease increases the risk of acute rejection, de novo GN, thrombotic microangiopathy, proteinuria, and new-onset diabetes (50–53). In the pre-DAA period, HCV was associated with poorer outcomes and, thus, donors infected with HCV received a 20- to 25-point Kidney Donor Profile Index (KDPI) penalty. IFN-based therapies were largely avoided in the post-kidney transplantation setting because IFN can induce acute graft rejection (54,55). Fortunately, dedicated clinical trials in transplant recipients have shown that DAAs can be used safely after kidney transplantation, with excellent cure rates and without causing allograft dysfunction or acute rejection (Table 1) (56,57). A summary of real-world use of DAAs in recipients of kidney transplants confirmed high cure rates (97%) and low acute rejection rates (3%) (50). HCV-related, post-transplant GN is likely to be less common in transplant recipients who have received DAAs; however, it is important to note that de novo cryoglobulinemic GN has been described in patients infected with HCV who have been cured of HCV (32).

Because of the rapid rise in HCV-infected donor kidneys in the last decade (58–63), and the high rate of discard of these potentially robust organs, research protocols transplanting HCV-infected kidneys into recipients not infected with HCV, followed by DAA therapy to eradicate HCV, have been actively explored over the last 5 years. Single-center and multicenter clinical trials demonstrated outstanding cure rates when DAAs are begun pre-emptively (just before surgery) or within the first few days of kidney transplant (Table 2) (64–72). Whereas initial trials used a full treatment course, a recent pilot trial shortened DAA therapy to 4 weeks post-transplant and still achieved 100% cure of HCV, suggesting a shorter course may be a viable approach (67). Overall 1-year allograft outcomes have been excellent, although one case of post-transplant FSGS was considered to be possibly related to HCV infection or DAAs by study investigators (72).

Because of these promising trial results, many centers are now transplanting donors with HCV into recipients without HCV (66,73,74). Two recent analyses used United Network for Organ Sharing data to show there has been a rapid rise in the acceptance of HCV+ organs (75,76). Potluri and colleagues (76) not ed that, by 2019, patients seronegative for HCV received the majority of kidneys transplanted from donors who were HCV viremic. Results of real-world studies that have transplanted HCV-viremic kidneys into donors who were HCV naïve have encountered delays in initiation of DAAs, yet still report excellent cure rates (66,77). However, delay in access to DAAs, while awaiting insurance approval, led to substantial numbers of patients experiencing elevated liver function tests and even a few cases of fibrosing cholestatic hepatitis (66,77). These studies highlight the importance of starting DAAs immediately post-transplant. Using a Markov state transition simulation model, Eckman et al. showed that pre-emptive DAA strategies were cost-effective when increased utilization of donors infected with HCV shortened waitlist time by at least 0.9 years (78).

Many have questioned whether the “KDPI penalty” is still needed in the era of DAA therapy. The large KDPI penalty for kidneys from donors with HCV may discourage centers from transplanting these organs. In an analysis by Potluri et al. (76), HCV-viremic kidneys that were transplanted into recipients who were HCV seronegative had similar 1-year eGFRs to HCV-nonviremic kidneys when matched on predictors of organ quality, except HCV, despite the much worse KDPI scores assigned to the HCV-viremic kid neys. Additionally, 1-year allograft outcomes for HCV-viremic kidneys were not meaningfully different if transplanted into recipients who were HCV seronegative versus HCV seropositive. These results provide important evidence that the current KDPI penalty for HCV status may not accurately assess the quality of kidneys from donors with HCV in the era of curative DAAs (76,79).

Conclusions and Future Directions

The ability to cure HCV has led to dramatic changes in standard-of-care management of HCV in patients with kidney disease and important efforts to expand the kidney donor pool. Further research is needed to elucidate the effect of HCV eradication on CKD progression, dialysis morbidity and mortality, and recipients of kidney transplants. It is possible that, in the near future, assuming long-term studies confirm that donors with HCV do not lead to worse allograft survival, the KDPI penalty for HCV infection can be removed. Finally, standardizing the optimal timing and duration of DAA therapy for patients without HCV who undergo transplantation from a donor with HCV will hopefully move this practice to standard of care. In summary, considering the ample evidence demonstrating worse outcomes in patients who suffer from both comorbidities, and the high efficacy and tolerability of DAAs, curing HCV should be prioritized in patients with kidney disease.

Disclosures

M.E. Sise reports receiving research funding from Abbvie, Gilead Sciences, and Merck; and serving as a scientific advisory board member for Gilead Sciences. All remaining authors have nothing to disclose.

Funding

This work was supported by National Institutes of Health grants T32 DK007028 and K23 DK 117014, and a Massachusetts General Hospital Claflin Distinguished Scholars Award (to M.E. Sise).
Improving organ utilization to help overcome the tragedies of the opioid epidemic.

AM J Transplant

Characteristics of deceased solid organ donors and screening for hepatitis B, C, and human immunodeficiency viruses.

Ann ambhotla P, Bowman J, Levi ME, Brooks JT, Basavaraju SV: Characteristics of deceased solid organ donors and screening for hepatitis B, C, and human immunodeficiency viruses – United States, 2010 – 2017. MMWR Mortal Wkly Rep 68: 61–66, 2019 https://doi.org/10.15585/mmwr.mm6803a2

Durand CM, Bowring MG, Thomas AG, Kucirka LM, Massie AB, Ishaque T, Bae S, Shaffer AL, Gilday DL, Eyster M, Blessing ME, Selvaggi L, Fialdini R, Kaul S, Sulkowski MS, Desai NM, Nair S, Cseprekal O, Yazawa M, Talwar M, Balara VP, Fabrizi F, Penatti A, Messa P, Martin P, Dixit V, Mussetti L, Murphy J, Krajewski K, Pileggi T, Kambham N, Cekerevac M, Kung A, Feldman J, Lee E, Mysliwiec M, Silverman S, Garonzik Wang J, Sulkowski M, Desai N, Segev DL, Durand CM, Bowring MG, Brown JR, Friedewald JJ, Prender J, eines J, Baron M, Williams WW, Gustafson JL, Desai NM, Barnaba B, Norman SP, Doshi M, Santt T, Aull MJ, Levitsky J, Belsha DS, Chung RT, Reese PP: Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An open-label study of combined glecaprevir and pibrentasvir to treat recipients of transplanted kidneys from deceased donors with hepatitis C virus infection. J Am Soc Nephrol 31: 2678–2687, 2020 https://doi.org/10.1681/ASN.20200508683284337

Sise ME, Strohbehn IA, Chute DF, Gustafson J, Van Deelen VM, Smith JR, Gentile C, Wojciechowski D, Williams WW, Elias N, Chung RT: Preemptive anti-viral prophylaxis in kidney transplantation from hepatitis C-viremic donor to uninfected recipient kidney transplantation. Kidney Int Rep 5: 459–467, 2020 https://doi.org/10.1016/j.ekir.2020.01.032280841

Durand CM, Bowring MG, Brown JR, Chatterton MA, Mas-saccesi G, Bair N, Wesson R, Reyad A, Naqvi FF, Ostrander D, Sugumar J, Segel DV, Gandrakowska M, Segev DL, Durand CM, Bowring MG, Brown DM, Chatterton MA, Mas-saccesi G, Bair N, Wesson R, Reyad A, Naqvi FF, Ostrander D, Sugumar J, Segel DV, Gandrakowska M, Segev DL, Vlahakis NE, Pabst FT, Cabello DV: Direct, antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: An open-label nonrandomized trial. Ann Intern Med 168: 533–540, 2018 https://doi.org/10.7326/M18-074930083748

Goldberg DS, Abl PT, Reese PP, THINKER Trial Investigators: Transplanting HCV-infected kidneys into uninfected recipients. N Engl J Med 377: 1105, 2018 https://doi.org/10.1056/NEJMoa170931528902585

Kapila N, Menon KVN, Al-Khalloufi K, Vanatta JM, Murgas C, Reino D, Eabard S, Shaw JJ, Agrawal N, Khraouzani S, Navas V, Sheffield C, Rahman AU, Castillo M, Lindeymer CC, Miller C, Quintini C, Zervos XB: Hepatitis C virus NAT-positive solid organ allografts transplant recipients: Antiviral treatment outcomes – a real-world experience. Hepatology 72: 32–41, 2020 https://doi.org/10.1002/hep.3110131365775

Molnar MZ, Ahsar A, Tsujita M, Talwar M, Balaraman V, Bhatta A, Podila PSB, Kothadia A, Agnihum UA, Malikabakal B, Satapathy SK, Eason JD: Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: Single center experience. Am J Transplant 19: 3046–3057, 2019 https://doi.org/10.1111/ajt.1553103156549

Durand CM, Barnaba B, Yu S, Brown DM, Chatterton MA, Bair N, Naqvi FF, Sulkowski M, Segev DL, Desai NM: Four-week direct-acting antiviral prophylaxis for kidney transplantation from hepatitis C-viremic donors to hepatitis C-negative recipients: An open-label nonrandomized study. Ann Intern Med 174: 137– 148, 2021 https://doi.org/10.7326/M20-14638294607

Sise ME, Goldberg DS, Kort SJ, Schaubel DE, Allowall R, Durand CM, Fontana RJ, Brown RS Jr, Friedewald JJ, Prender J, Sinski JS, Landris J, Fernandez M, Phillips CC, Woodles E, Rike-Shields A, Sherman KE, Elias N, Williams WW, Gustafson JL, Desai NM, Barnaba B, Norman SP, Doshi M, Santt T, Aull MJ, Levitsky J, Belsha DS, Chung RT, Reese PP: Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An open-label study of combined glecaprevir and pibrentasvir to treat recipients of transplanted kidneys from deceased donors with hepatitis C virus infection. J Am Soc Nephrol 31: 2678–2687, 2020 https://doi.org/10.1681/ASN.20200508683284337

Kapila N, Al-Khalloufi K, Bejarano PA, Vanatta JM, Zervos XB: Fibrosing cholestatic hepatitis after kidney transplantation from HCV-viremic donors to HCV-negative recipients: A unique complication in the DAA era. Am J Transplant 20: 600–605, 2020 https://doi.org/10.1111/ajt.155313448549
78. Eckman MH, Woodle ES, Thakar CV, Alloway RR, Sherman KE: Cost-effectiveness of using kidneys from HCV-viremic donors for transplantation into HCV-uninfected recipients. *American Journal of Kidney Diseases* 75: 857–867, 2020 https://doi.org/10.1053/j.ajkd.2019.11.005. PubMed PMID: 32081494.

79. Yazawa M, Balaraman V, Tsujita M, Azhar A, Talwar M, Bhalla A, Potukuchi PK, Eason JD, Kovesdy CP, Molnar MZ: Donor hepatitis C antibody positivity misclassifies kidney donor profile index in non-hepatitis C-infected donors: time to revise the kidney donor profile index - a retrospective cohort study. *Transpl Int* 33: 1732–1744, 2020 https://doi.org/10.1111/tri.1374332935416

Received March 16, 2021 Accepted May 21, 2021